Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 10/20 | 0.40 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
| ▸ | HTR3B | O95264 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802783 | 0.85 | HTR2C (0.42) | HTR1AADRB1HTR6HTR2CHTR3E | |
| SCHEMBL5803186 | 0.80 | HTR6 (0.49) | HTR1AHTR6HTR3A | |
| SCHEMBL5802772 | 0.78 | HTR6 (0.39) | HTR1AHTR6HTR2CDRD2HTR3A | |
| Hydrochloric Acid SCHEMBL5803718 | 0.77 | HTR6 (0.38) | HTR1AHTR6HTR2CDRD2HTR3A | |
| SCHEMBL3626769 | 0.76 | HTR6 (0.48) | HTR1AADRB1HTR6DRD3HTR7 | |
| SCHEMBL5804780 | 0.73 | DRD2 (0.41) | HTR1AHTR6DRD2DRD3 | |
| SCHEMBL5805845 | 0.72 | HTR2C (0.41) | HTR2C | |
| SCHEMBL5803260 | 0.72 | HTR2C (0.41) | HTR2C | |
| SCHEMBL3622734 | 0.72 | HTR6 (0.55) | HTR1AHTR6DRD2HTR7 | |
| SCHEMBL3619404 | 0.72 | HTR6 (0.49) | HTR1AADRB1HTR6DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | claimed |
| US-20060142269-A1 | New compounds | BIOVITRUM AB (SE) | 2006-06-29 | — | — | US | disclosed |
| WO-2006062481-A1 | NEW BENZOFURAN DERIVATIVES AND THEIR USE IN THE TREATMENT OF OBESITY, TYPE II DIABETES AND CNS DISORDERS . | BIOVITRUM AB (SE) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142269-A1 | New compounds | GPR119, GLP1R, IAPP | HTR1A 694/4885SLC6A2 796/4885ADRB1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.